^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LB1901

    i
    Other names: LB1901
    Associations

    News

    Trials
    Company:
    Legend Biotech
    Drug class:
    CD4-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    almost4years
    LB1901: A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL) (AACR 2022)
    Pts may receive optional bridging therapy and receive lymphodepleting chemotherapy with fludarabine 30mg/m2/day and cyclophosphamide 300mg/m2/day (Flu-Cy), for 3 days followed by LB1901. Secondary endpoints include overall response rate; duration of response; CAR-positive T cell counts and CAR transgene level in blood; and presence of anti-CAR antibody response. Exploratory endpoints include preliminary efficacy, pharmacokinetics, and CD4+ T cell counts.
    Clinical • P1 data • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    CD4 expression
    |
    cyclophosphamide • fludarabine IV • LB1901
    4years
    LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Legend Biotech USA Inc | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    LB1901
    over4years
    LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Recruiting, Legend Biotech USA Inc | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    LB1901
    over4years
    LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Legend Biotech USA Inc | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2023
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    LB1901
    almost5years
    [VIRTUAL] Preclinical analysis of an autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy for relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). (ASCO 2021)
    Altogether, the in vitro and in vivo studies showed that LB1901 did not ?mask? the CD4 antigen but exhibited potent anti-tumor activity without off-target effects . A phase 1 study of LB1901 CAR-T in patients with relapsed or refractory PTCL or CTCL is ongoing in the US to assess the safety and tolerability of LB1901 CAR-T (NCT04712864).
    Preclinical • CAR T-Cell Therapy
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    LB1901
    5years
    LB1901-TCL-1001: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Legend Biotech USA Inc
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    LB1901